AI Engines For more Details: Perplexity Kagi Labs You
Topical Anesthesia: Benoxinate hydrochloride works by blocking nerve impulses in the eye, leading to temporary numbness of the cornea and conjunctiva. This allows eye examinations and procedures to be performed with minimal discomfort to the patient.
Diagnostic Procedures: It is commonly used to facilitate various diagnostic procedures, including but not limited to applanation tonometry, gonioscopy, and examination of the anterior segment of the eye. By numbing the eye's surface, benoxinate hydrochloride helps improve patient cooperation and comfort during these examinations.
Minor Eye Surgeries: Benoxinate hydrochloride may be used as a local anesthetic agent for minor eye surgeries, such as corneal abrasion repair, foreign body removal, and lid procedures. It provides effective pain relief during the surgical procedure while allowing the patient to remain conscious.
Short Duration of Action: The anesthetic effect of benoxinate hydrochloride typically lasts for a short duration, usually up to 15-20 minutes after instillation. This rapid onset and short duration of action make it suitable for use in quick, office-based procedures.
Minimal Systemic Absorption: When applied topically to the eye, benoxinate hydrochloride has minimal systemic absorption, reducing the risk of systemic side effects. However, local adverse reactions such as eye irritation, burning sensation, and transient blurred vision may occur, but they are usually mild and self-limiting.
Contraindications: Benoxinate hydrochloride should not be used in patients with a known hypersensitivity to local anesthetics of the ester type. Additionally, caution is advised in patients with corneal abrasions or lesions, as the use of topical anesthetics in these cases may delay healing and increase the risk of corneal complications.
Precautions: Healthcare providers should use benoxinate hydrochloride cautiously in patients with preexisting eye conditions, such as dry eye syndrome, glaucoma, or corneal dystrophies, as these conditions may increase the risk of adverse effects or complications.
Safe Handling: Proper techniques for instilling eye drops should be followed to minimize the risk of contamination and infection. Additionally, patients should be instructed on proper administration techniques and advised to avoid touching the tip of the dropper to prevent contamination.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
| Acne | 0.6 | 0.4 | 0.5 |
| ADHD | 3.1 | 0.9 | 2.44 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.2 | 1.7 | 0.29 |
| Allergies | 4.4 | 3.6 | 0.22 |
| Allergy to milk products | 1.7 | 1 | 0.7 |
| Alopecia (Hair Loss) | 0.9 | 0.9 | |
| Alzheimer's disease | 5.7 | 4.2 | 0.36 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3 | 1.1 | 1.73 |
| Ankylosing spondylitis | 3 | 0.7 | 3.29 |
| Anorexia Nervosa | 1.2 | 2.2 | -0.83 |
| Antiphospholipid syndrome (APS) | 0.7 | 0.3 | 1.33 |
| Asthma | 3.9 | 2.7 | 0.44 |
| Atherosclerosis | 1.4 | 2.2 | -0.57 |
| Atrial fibrillation | 3 | 2.2 | 0.36 |
| Autism | 8 | 6.9 | 0.16 |
| Autoimmune Disease | 0.6 | 1 | -0.67 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 1.5 | 1.5 | |
| Bipolar Disorder | 1.5 | 1.4 | 0.07 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 0.8 | 0.8 | |
| Cancer (General) | 0.9 | 1.4 | -0.56 |
| Carcinoma | 3.8 | 2.2 | 0.73 |
| Celiac Disease | 2 | 3 | -0.5 |
| Cerebral Palsy | 1.8 | 0.8 | 1.25 |
| Chronic Fatigue Syndrome | 3.3 | 3.7 | -0.12 |
| Chronic Kidney Disease | 3 | 2.4 | 0.25 |
| Chronic Lyme | 0.1 | 0.8 | -7 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.8 | 1.7 | 0.06 |
| Chronic Urticaria (Hives) | 0.8 | 1.4 | -0.75 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.8 | -0.14 |
| Cognitive Function | 2.7 | 1.6 | 0.69 |
| Colorectal Cancer | 7.7 | 2.6 | 1.96 |
| Constipation | 0.8 | 1 | -0.25 |
| Coronary artery disease | 1 | 2.4 | -1.4 |
| COVID-19 | 5.5 | 7.6 | -0.38 |
| Crohn's Disease | 6.5 | 5 | 0.3 |
| Cushing's Syndrome (hypercortisolism) | 0.8 | -0.8 | |
| cystic fibrosis | 1.1 | -1.1 | |
| deep vein thrombosis | 1.8 | 1.1 | 0.64 |
| Denture Wearers Oral Shifts | 0.7 | 0.7 | |
| Depression | 8.9 | 6.8 | 0.31 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.2 | 1.6 | -0.33 |
| Endometriosis | 2.2 | 1.4 | 0.57 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 2.2 | 2.3 | -0.05 |
| erectile dysfunction | 0.9 | 0.3 | 2 |
| Fibromyalgia | 2.6 | 2.6 | 0 |
| Functional constipation / chronic idiopathic constipation | 3 | 3.4 | -0.13 |
| gallstone disease (gsd) | 1.9 | 1.6 | 0.19 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.6 | 0.3 | 4.33 |
| Generalized anxiety disorder | 2 | 2.4 | -0.2 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.1 | 1.5 | 0.4 |
| Graves' disease | 1.6 | 2.9 | -0.81 |
| Gulf War Syndrome | 0.8 | 1.9 | -1.37 |
| Halitosis | 1.4 | 0.3 | 3.67 |
| Hashimoto's thyroiditis | 3.1 | 1.4 | 1.21 |
| Heart Failure | 2.2 | 2.2 | 0 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 0.8 | 0.3 | 1.67 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.6 | -0.2 |
| hyperglycemia | 0.8 | 2.1 | -1.63 |
| Hyperlipidemia (High Blood Fats) | 1.3 | 0.3 | 3.33 |
| hypersomnia | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 3.6 | 3.4 | 0.06 |
| Hypothyroidism | 0.4 | 0.9 | -1.25 |
| Hypoxia | 2.3 | 0.8 | 1.87 |
| IgA nephropathy (IgAN) | 1.6 | 2.7 | -0.69 |
| Inflammatory Bowel Disease | 5.2 | 5.6 | -0.08 |
| Insomnia | 1.7 | 2.7 | -0.59 |
| Intelligence | 1.1 | 0.5 | 1.2 |
| Intracranial aneurysms | 1 | 0.9 | 0.11 |
| Irritable Bowel Syndrome | 5.4 | 4.7 | 0.15 |
| ischemic stroke | 2.1 | 1.1 | 0.91 |
| Liver Cirrhosis | 5.5 | 5 | 0.1 |
| Long COVID | 5.4 | 4.8 | 0.13 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.8 | 1.2 | -0.5 |
| Lymphoma | 0.3 | 0.3 | |
| Mast Cell Issues / mastitis | 0.5 | 0.6 | -0.2 |
| ME/CFS with IBS | 0.9 | 0.9 | 0 |
| ME/CFS without IBS | 1.4 | 1.4 | 0 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.4 | 1 | -1.5 |
| Metabolic Syndrome | 5.9 | 6.6 | -0.12 |
| Mood Disorders | 8.6 | 5.8 | 0.48 |
| multiple chemical sensitivity [MCS] | 1 | 1 | |
| Multiple Sclerosis | 5.8 | 3.8 | 0.53 |
| Multiple system atrophy (MSA) | 1.6 | 0.3 | 4.33 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 0.3 | 2.3 | -6.67 |
| Neuropathy (all types) | 1 | 1.3 | -0.3 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.3 | 3.3 | 0 |
| NonCeliac Gluten Sensitivity | 1.8 | 0.6 | 2 |
| Obesity | 7.9 | 7.2 | 0.1 |
| obsessive-compulsive disorder | 2.5 | 3.6 | -0.44 |
| Osteoarthritis | 1.2 | 1.3 | -0.08 |
| Osteoporosis | 1.6 | 2 | -0.25 |
| pancreatic cancer | 1.4 | 0.6 | 1.33 |
| Parkinson's Disease | 5.8 | 4.9 | 0.18 |
| Polycystic ovary syndrome | 3.8 | 2.6 | 0.46 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.6 | 0.4 | 0.5 |
| primary biliary cholangitis | 1.2 | 1.4 | -0.17 |
| Primary sclerosing cholangitis | 2.5 | 1.1 | 1.27 |
| Psoriasis | 2.1 | 3.1 | -0.48 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.3 | 4 | 0.32 |
| Rosacea | 0.4 | 1 | -1.5 |
| Schizophrenia | 4.7 | 2.8 | 0.68 |
| scoliosis | 0.3 | 0.3 | 0 |
| Sjögren syndrome | 2 | 2.2 | -0.1 |
| Sleep Apnea | 1.4 | 1.4 | 0 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.6 | 0.1 | 15 |
| Stress / posttraumatic stress disorder | 3.1 | 3.2 | -0.03 |
| Systemic Lupus Erythematosus | 3.3 | 1.2 | 1.75 |
| Tic Disorder | 1.1 | 1.7 | -0.55 |
| Tourette syndrome | 1.3 | 0.3 | 3.33 |
| Type 1 Diabetes | 3.6 | 2.6 | 0.38 |
| Type 2 Diabetes | 7.1 | 6.4 | 0.11 |
| Ulcerative colitis | 3.6 | 5.7 | -0.58 |
| Unhealthy Ageing | 4.4 | 2.7 | 0.63 |
| Vitiligo | 1.6 | 1.4 | 0.14 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
